<DOC>
	<DOCNO>NCT01859702</DOCNO>
	<brief_summary>The purpose study determine moxifloxacin aqueous penetration dose combination drug Vigadexa preoperatively cataract patient .</brief_summary>
	<brief_title>Pharmacokinetic Evaluation Moxifloxacin VigadexaÂ® Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing Cataract Surgery Patients</brief_title>
	<detailed_description />
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Requires cataract surgery ; Acceptable health status ( medical history , physical , laboratory ophthalmologic exam ) ; Able follow instruction willing attend study visit ; Other protocoldefined inclusion criterion may apply . Any known suspected allergies/hypersensitivity investigational test product component ; History invasive intraocular surgery eye operate , within 4 month enrollment ; Use medication , specify protocol ; Severe dry eye syndrome ; Use contact lenses two day surgery last visit ; External eye disease , infection inflammation eye eyelids ; Excessive bleeding tendency ; No vision eye include study ; Pregnant breastfeeding ; Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Aqueous Humor</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Vigadexa</keyword>
</DOC>